Literature DB >> 11374680

Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature.

C Zamora1, J Sahel, D G Cantu, L Heyries, J P Bernard, C Bastid, M J Payan, I Sielezneff, L Familiari, B Sastre, M Barthet.   

Abstract

OBJECTIVE: Despite a better understanding of these conditions, intraductal papillary or mucinous tumors (IPMT) of the pancreas still present difficulty relating to the predictive factors of malignancy and the risk of relapse after surgical resection. The aim of this study was to report on our experience and to compare it to previously published cases.
METHODS: We studied retrospectively 26 patients (mean age 60.3 yr) presenting with IPMT. Of the 26 patients, 19 had surgical resection and seven did not. The main clinical feature was acute pancreatitis occurring in 38% of the patients. Segmental pancreatectomy was performed in all the cases. At pathological assessment of resection margins, tumor resection was considered as complete in 17 cases. Margins exhibited benign mucinous involvement, and resection was considered to be incomplete in one multifocal case and in one case with diffuse spread of the tumor.
RESULTS: A total of 11 tumors were benign and five were malignant. Carcinomas were invasive in four cases (two invading the pancreatic parenchyma, one the duodenum, and one the peripancreatic nodes) and in situ in one case. Malignancy was not diagnosed preoperatively except when invasion was evident (duodenal spread). Although main pancreatic duct type and obstructive jaundice appeared as suggestive features for the risk of malignancy, no reliable preoperative predictive factors for malignancy could be identified as regarding to clinical parameters, biological examinations, carcinoembryonic antigen or CA19-9 levels in serum or in pure pancreatic juice, imaging, and cytological methods. Within 40.8 months mean follow-up after surgery (range 2-96 months), three patients (16%), two with malignant and one with benign tumor, had tumor relapse after respectively 7, 27, and 14 months. Margins were positive without malignant features in the two malignant cases and negative in the other case. Tumor relapse was malignant with diffuse spreading in the three cases, and the patients died within 34 months after surgical resection.
CONCLUSIONS: Our series and the review of the literature indicate that preoperative indicators of malignancy in IPMT are still lacking. Concerning resection margins, complete tumor resection is usually possible by segmental pancreatectomy. Malignant relapses are not exceptional. Incomplete resection and diffuse or multifocal tumor represent poor prognostic factors. Total pancreatectomy should be considered in such cases.

Entities:  

Mesh:

Year:  2001        PMID: 11374680     DOI: 10.1111/j.1572-0241.2001.03689.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  Diagnostic and Therapeutic Applications of EUS in Pancreatic Disease.

Authors:  Michelle A Anderson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-10

2.  A gastric fistula with a pancreatic mucinous tumor.

Authors:  Mehmet Ibiş; Seyfettin Köklü; Omer Başar; Ibrahim Ertuğrul; Selçuk Dişibeyaz; Aysel Ulker
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Minute invasive ductal carcinoma of the residual pancreas after distal pancreatectomy for intraductal papillary-mucinous tumor.

Authors:  Toshiyuki Moriya; Wataru Kimura; Fumiaki Sakurai; Shuho Semba; Koichiro Ozawa; Ichiro Hirai; Akira Fuse
Journal:  Int J Gastrointest Cancer       Date:  2002

4.  Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer.

Authors:  Huan-Li Xu; Xin Zhao; Ke-Ming Zhang; Wei Tang; Norihiro Kokudo
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

5.  Natural history of intraductal papillary mucinous neoplasia: How much do we really know?

Authors:  Chad G Ball; Thomas J Howard
Journal:  World J Gastrointest Surg       Date:  2010-10-27

6.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 7.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

Review 8.  Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management.

Authors:  Claudio Bassi; Michael G Sarr; Keith D Lillemoe; Howard A Reber
Journal:  J Gastrointest Surg       Date:  2007-12-19       Impact factor: 3.452

9.  Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms.

Authors:  Benjamin M Weinberg; Brennan M R Spiegel; James S Tomlinson; James J Farrell
Journal:  Gastroenterology       Date:  2009-10-08       Impact factor: 22.682

10.  Predictors of recurrence in intraductal papillary mucinous neoplasm: experience with 183 pancreatic resections.

Authors:  Megan Winner; Irene Epelboym; Helen Remotti; James L Lee; Beth A Schrope; John A Chabot; John D Allendorf
Journal:  J Gastrointest Surg       Date:  2013-06-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.